VA
VR Adviser Portfolio holdings
AUM
$1.33B
This Quarter Return
+31.72%
1 Year Return
+6.92%
3 Year Return
+862.77%
5 Year Return
+1,580.48%
10 Year Return
–
AUM
$511M
AUM Growth
+$511M
(+22%)
Cap. Flow
+$15.6M
Cap. Flow
% of AUM
3.05%
Top 10 Holdings %
Top 10 Hldgs %
80.15%
Holding
29
New
13
Increased
1
Reduced
1
Closed
7
Top Buys
| 1 |
Athira Pharma
ATHA
|
$28.1M |
| 2 |
Cardiff Oncology
CRDF
|
$18M |
| 3 |
IMV
IMV Inc. Common Shares
IMV
|
$17.8M |
| 4 |
Celldex Therapeutics
CLDX
|
$11.9M |
| 5 |
MTCR
Metacrine, Inc. Common Stock
MTCR
|
$11.7M |
Top Sells
| 1 |
VXRT
Vaxart
VXRT
|
$24.5M |
| 2 |
MYOV
Myovant Sciences Ltd.
MYOV
|
$17.4M |
| 3 |
NARI
Inari Medical, Inc. Common Stock
NARI
|
$11.4M |
| 4 |
AVDL
Avadel Pharmaceuticals
AVDL
|
$8.55M |
| 5 |
ADAP
Adaptimmune Therapeutics
ADAP
|
$7.83M |
Sector Composition
| 1 | Healthcare | 72.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
89bio
ETNB
$1.37B
| – | – |
-291,140
| Closed | -$5.8M |
|
|
AVDL
27
Avadel Pharmaceuticals
AVDL
$1.42B
| – | – |
-1,057,827
| Closed | -$8.55M |
|
|
ADAP
28
Adaptimmune Therapeutics
ADAP
$13.9M
| – | – |
-781,940
| Closed | -$7.83M |
|